Clinical evidence has shown that the intracoronary delivery of mononuclear cells (MNCs) or mesenchymal stem cells (MSCs) can improve the ejection fraction and reduce the infarct size in patients with acute myocardial infarction. Stem cells are introduced using a balloon to temporarily occlude flow and a special catheter injects cells into the infarct-related artery. Intracoronary cell administration obviously seems to be advantageous for tissue repair of infarcted heart muscle by supplying the entire heart muscle compartment. However, safety profiles might be different from the cell type, cellular product size, and characterization of the cell population in intracoronary administration. Therefore, we conducted a systematic review to compare efficacy and safety profiles in intracoronary injection of MNC to MSC using a network meta-analysis.
Randomized controlled trials in patients with AMI receiving MNC or MSC therapy were identified from PubMed, Embase, and Cochrane library from inception to January 2020 41 RCTs included in the analysis.
Using network meta-analysis, which one is better effect on improvement of LVEF and which one is safer in terms of incidence rates of all-cause mortality, revisualization, restenosis SAE and rehospitalization for HF between MNC and MSC will be analyzed.

Acknowledgement
This research was supported by a grant (18172MFDS182) from the Ministry of Food & Drug Safety in 2018.